In this paper, we report the use of lead sulfi de quantum dot (PbS QD) bioconjugates as near infrared (NIR) contrast agents for targeted molecular imaging with expanded emission wavelengths beyond 1000 nm. The red-shifted emission band, coupled with the small particle size, which will facilitate clearance, both afford PbS QDs unique properties for noninvasive, high resolution in vivo NIR imaging applications. We have performed imaging experiments at the molecular level using surface-modifi ed PbS NIR QDs, together with our lab-built NIR imaging system. This novel instrumentation and fl uorescent contrast agent have enabled us to study the relatively unexplored NIR biomedical imaging spectral region of 900-1200 nm. Preliminary experimental results indicate that PbS-QD/antibody bioconjugates are promising candidates for targeted NIR molecular imaging and future in vivo NIR tissue imaging applications.
Introduction
In this paper, we report the fi rst attempt to use lead sulfi de (PbS) near-infrared (NIR) quantum dot (QD) bioconjugates with imaging wavelengths beyond 1000 nm as molecular-specifi c contrast agents for targeted imaging applications. For example, the photoluminescent band of PbS QDs shown in Figure 1 peaks at around 1010 nm in phosphate buffered saline (PBS), and their excitation spectrum spans from the UV to NIR region (Zhu et al 2007) . Before surface modifi cation, the average size of the PbS QDs is ~4-5 nm, with no signifi cant increase in size observed after surface coating of the particles (Zhu et al 2007) . The longer emission wavelength, coupled with the small particle size, which facilitates clearance (Zimmer et al 2006) , both afford PbS QDs unique properties for noninvasive, high resolution in vivo NIR imaging applications (Kim et al 2004; Chang et al 2005; Michalet et al 2005; Cai et al 2006) . The "therapeutic window" of the NIR spectrum, 700-1200 nm, enables light to penetrate several centimeters deep into the tissue, thereby making PbS QDs ideal for in vivo deep-tissue imaging and diagnostics (Wilson and Jacques 1990; Weissleder 2001; Michalet et al 2005) . While numerous groups have reported various fl uorescent NIR imaging contrast agents, most of these agents possess the emission spectral range of 700-900 nm (Medintz et al 2005; Michalet et al 2005; Cai et al 2006) . However, to date, the NIR spectral region of 900-1200 nm has not been suffi ciently investigated for biomedical imaging applications, because of the lack of suitable contrast agents, as well as imaging systems, etc (Wilson and Jacques 1990; Michalet et al 2005) .
To address these issues, the current study demonstrates how we have combined novel instrumentation with surface modifi ed PbS QDs, allowing us to explore the NIR spectral region, as noted above. Specifi cally, we have carried out molecular level imaging experiments using our surface-modifi ed PbS NIR QDs (Zhu et al 2007) together with our lab-built NIR imaging system. These experiments, discussed below, were conducted with a view toward future in vivo animal screening. To explain, a wide range of visible light (500-700 nm) has been used as excitation for PbS QDs imaging. The red-shifted excitation band of the NIR QDs, on the other hand, not only provides deeper penetration into tissue than the excitation band of visible QDs (Wu et al 2003; Kim et al 2004; Michalet et al 2005) , but also avoids most of the absorption peaks of tissue fl uorophores that usually give strong auto-fl uorescence backgrounds (Richards-Kortum and Sevick-Muraca 1996) . Hence, the NIR imaging method presented will potentially provide appealing results for both in vivo tissue screening and imaging applications.
Compared with traditional organic NIR fl uorophores, the absorption and photoluminescent spectra of semiconductor nanocrystals can be easily tailored by changing the size and shape of the particles. This provides fl exibility in many biological and clinical imaging applications (Hines and Scholes 2003; Chang et al 2005; Medintz et al 2005; Cai et al 2006) . Furthermore, both the chemical and physical environmental stabilities of quantum dots, as well as their high quantum yield effi ciency, make them highly desirable as fl uorescent imaging contrast agents (Chan and Nie 1998; Medintz et al 2005; Michalet et al 2005) . PbS QDs used in the following work are synthesized (Hines and Scholes 2003) and surface modifi ed in accordance with methods presented in previous publications (Medintz et al 2005; Zhu et al 2007) .
Materials and methods
The development of molecular-specifi c imaging techniques remains of great interest for diagnostic applications (Wu et al 2003; Michalet et al 2005) . In particular, contrast agents that specifi cally target disease-associated biomarkers provide a convenient means for cancer screening and detection at the onset of disease, a period of time that is critical for both effective diagnosis and treatment (Chan and Nie 1998; Wu et al 2003; Loo et al 2005; Michalet et al 2005) . Our study specifi cally addresses the expression of human epidermal growth factor receptor 2 (HER2), which is over-expressed in living human breast carcinoma cells (Wu et al 2003; Loo et al 2005) . To image the expression of these receptors, two kinds of QD/antibody bioconjugates are prepared. Both anti-HER2 and anti-immunoglobulin G (anti-IgG) antibodies are conjugated to PbS QDs, as specifi c and nonspecifi c imaging contrast agents, respectively (Wu et al 2003; Loo et al 2005) .
QD/antibody conjugation
The modifi ed PbS QDs surfaces are terminated with carboxyl groups (Zhu et al 2007) , and they are attached to antibodies through EDC and Sulfo-NHS cross-linkers (Wu et al 2003; Chang et al 2005) . Briefl y, ~0.2 nmol surface-modifi ed PbS QDs suspended in 1x phosphate-buffered saline (PBS) (pH 7.2) are activated with EDC (1mg) and Sulfo-NHS (1mg) (Pierce, Rockford, IL) for 30 min by gentle stirring. Following the activation, excess EDC and Sulfo-NHS are removed from the reaction with desalt spin columns (Pierce, Rockford, IL). The fi ltered solution is evenly split into two aliquots, ~0.1 nmol-activated QDs per aliquot. Anti-HER2 (~0.22 nmol) (Labvision, Fremont, CA) and anti-IgG (~0.22 nmol) (Sigma-Aldrich, St. Louis, MO) antibodies are added to each aliquot, respectively, and allowed to react for 0.5-1 h, with gentle stirring. Polyethylene glycol-amine (PEG-NH 2 ) and Tris buffer (pH 7.0) are then added at the end of the conjugation to react with excess carboxyl and activated ester groups. These QD/antibody conjugates are allowed to react Abbreviations: PbS, lead sulfi de; QD, quantum dots; TEM, transmission electron microscopy.
Lead sulfi de near-infrared quantum dot bioconjugates for targeted molecular imaging overnight at 4 °C and then readied for targeted imaging (Wu et al 2003; Chang et al 2005; Loo et al 2005) .
Cell culture HER2 over-expressed SK-BR-3 human breast cancer cells are cultured in McCoy's 5A modifi ed medium (ATCC, Manassas, VA) with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA) and 1% antibiotics. Cells are allowed to grow on Lab-Tek 4-chambered coverglass (Nalge Nunc Inc., Rochester, NY) for 24 h at 37 °C and 5% CO 2 incubation before targeting.
QD-bioconjugates targeting of cells
Culture medium from each of the cell chambers is removed, and cells are rinsed with PBS (0.6 mL/chamber). 0.3 mL paraformaldehyde (3%-4%) in PBS is added to each chamber to fi x the cells, and this reaction is allowed to stand for 15 min at room temperature (r.t.) (Wu et al 2003) . The fi xed cells are washed 2-3 times with PBS (0.6 mL/chamber) to eliminate the infl uence of the fi xing solution. Following the washing, 2% BSA/PBS solution is added to three chambers, with 0.3 mL/chamber, to block the nonspecifi c binding sites on the cell surface (Wu et al 2003) . This process takes 10-15 min at room temperature. After blocking, all 3 chambers of the cells are washed with PBS. PbS-QDs/anti-HER2 conjugates in PBS 0.4 mL (~50 nM or ~35 nM) are then added to one chamber of the blocked cells. Meanwhile, the same amount and concentration of PbS-QDs/anti-IgG conjugates in PBS are added to another chamber of blocked cells. 0.4 mL PBS is added to the third chamber as a control sample. The targeting process is allowed to react for 3-4 h at r.t. on a gently moving orbital shaking plate, avoiding light. All of the cells in the three chambers are washed with PBS after the targeting process to remove free QD/bioconjugates. These QD-targeted cell samples and the control sample are fi xed and washed again. Finally, 0.4 mL PBS is added to each of the three chambers to preserve the moisture, and the samples are fi nally ready for imaging. 
Cell imaging

Toxicity of QD-bioconjugates to SK-BR-3 cells
The cytotoxicity introduced by our surface-modified PbS-QD/antibody conjugates in SK-BR-3 cells was studied with a LIVE/DEAD viability assay (Invitrogen). The same amount of SK-BR-3 cells are allowed to grow on Lab-Tek chambered coverglass (4 chambers) for 46 h at 37 °C and 5% CO 2 incubation and thoroughly rinsed with D-PBS (at least 3 times) to eliminate dead cells. The washed cells are incubated with testing particles over a period of 4 h at 37 °C before viability stains are applied. The stained cells are examined under fl uorescence and bright fi eld microscopy with a Zeiss Axiovert 200 M inverted microscope equipped with proper fi lter sets.
Results and discussion
Qualitatively, as shown in Figure 2 (taken with 40x objective) and Figure 3 (taken with 20x objective), PbS-QD/anti-HER2-targeted cells have the brightest luminescent images with the best contrast when compared with either cells targeted by PbS-QD/anti-IgG conjugates or control cells incubated with PBS. These results agree with previous reports (Chan and Nie 1998; Wu et al 2003; Loo et al 2005) . Since SK-BR-3 human breast cancer cells are HER2 over-expressed, they demonstrate more favorable binding effi ciency with the anti-HER2-conjugated QDs than with anti-IgG-conjugated QDs (Wu et al 2003; Loo et al 2005) . Therefore, the signifi cantly increased luminescent signal and image contrast in the NIR range may be particularly ascribed to the PbS QDs labeling of the HER2 receptors (Chan and Nie 1998; Wu et al 2003; Loo et al 2005) . It is worthwhile noting that both the luminescent intensities and contrast of PbS-QD/anti-IgG-targeted cells are much lower than those of the PbS-QD/anti-HER2-labeled cells. These same measurements are, however, still higher than those of the control sample, which has no detectable luminescent signal in the NIR (>800 nm) region (Figure 2 
Lead sulfi de near-infrared quantum dot bioconjugates for targeted molecular imaging (Wu et al 2003; Loo et al 2005) . It is also important to consider that improved image quality is expected after further optimization of the NIR imaging system. Aside from the development of effective contrast agents, still another important issue for in vivo imaging applications of quantum dots derives from their toxicity, which varies with different surface coatings (Medintz et al 2005; Delehanty et al 2006; Zhu et al 2007) . Preliminary results show that, within an acute incubation range of 4 h, cells incubated with anti-HER2-conjugated PbS QDs (~35 nM) (Figure 4) , antiIgG-conjugated PbS QDs (~35 nM) and unconjugated PbS QDs (~35 nM), respectively, show no signifi cant statistical difference in viability when compared with the control cells that are incubated with D-PBS. Notwithstanding these results, further tests are in progress to fully assess the toxicity of these QD bioconjugates over a longer period of time.
Moreover, the presented technique has unique advantages for future in vivo pre-cancer/cancer screening and imaging implementations particularly for the large cohort of breast cancer patients who are HER2 positive (Ross and Fletcher 1998; Horton 2001) . To explain, both the red-shifted excitation and emission bands of these PbS NIR QDs allow for deep-tissue diagnosis. The relatively small size of these particles is believed to facilitate body clearance which is crucial for in vivo implementations (Zimmer et al 2006) . Additionally, the general tunability of the emission peak of these nanoparticles offers fl exibility in clinical imaging applications (Hines and Scholes 2003; Medintz et al 2005; Cai et al 2006) . Although the relatively high cost of the current lab-built NIR imaging system might be one of the disadvantages of this technique, the total equipment expenses are expected to decrease dramatically with breakthroughs in sensor fabrication technologies and system optimization.
Conclusions
In conclusion, the main objective of this work is to study PbS QD bioconjugates with expanded emission wavelengths beyond 1000 nm as NIR contrast agents for targeted molecular imaging. We are able to study the relatively unexplored NIR biomedical imaging region of 900-1200 nm with the help of PbS QDs and the latest lab-built NIR imaging system. The proof-of-concept imaging results and the preliminary cytotoxicity tests all indicate that PbS-QD/anti-HER2 bioconjugates are promising candidates for targeted NIR molecular imaging with SK-BR-3 breast cancer cells and future in vivo NIR tissue imaging applications.
